NASDAQ : MNPR
Monopar Therapeutics Inc. — Financial statements
Healthcare · Biotechnology · United States
Last price 71.91 USD (Oct 29, 2026, 4:00 PM EDT) · Market cap 482.67M
Overview · Financial statements · Key statistics · Dividends · Company profile · Price history · Reports
Financial statements
Income statement
Fiscal year January - December; amounts in USD.
| TTM | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 | |
|---|---|---|---|---|---|---|
| Selling, General & Admin | 7.33M | 6.80M | 3.16M | 3.23M | 2.95M | 2.63M |
| Research & Development | 14.78M | 9.90M | 13.01M | 5.60M | 7.59M | 6.49M |
| Operating Expenses | 22.12M | 16.70M | 16.16M | 8.83M | 10.54M | 9.13M |
| Operating Income | -22.12M | -16.70M | -16.16M | -8.83M | -10.54M | -9.13M |
| Interest & Investment Income | 4.24M | 2.99M | 404.02K | 429.04K | 21.24K | 24.02K |
| Other Non Operating Income (Expenses) | 32.16K | 171.28K | ||||
| EBT Excluding Unusual Items | -17.84M | -13.72M | -15.59M | -8.40M | -10.52M | -9.10M |
| Pretax Income | -17.84M | -13.72M | -15.59M | -8.40M | -10.52M | -9.10M |
| Net Income | -17.84M | -13.72M | -15.59M | -8.40M | -10.52M | -9.10M |
| Net Income to Common | -17.84M | -13.72M | -15.59M | -8.40M | -10.52M | -9.10M |
| Shares Outstanding (Basic) | 8.18M | 7.41M | 3.79M | 2.76M | 2.54M | 2.49M |
| Shares Outstanding (Diluted) | 8.18M | 7.41M | 3.79M | 2.76M | 2.54M | 2.49M |
| EPS (Basic) | -2.18 | -1.85 | -4.11 | -3.04 | -4.13 | -3.65 |
| EPS (Diluted) | -2.18 | -1.85 | -4.11 | -3.04 | -4.13 | -3.65 |
| EBIT | -22.12M | -16.70M | -16.16M | -8.83M | -10.54M | -9.13M |
Balance sheet
Fiscal year January - December; amounts in USD.
| TTM | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 | |
|---|---|---|---|---|---|---|
| Cash & Equivalents | 52.76M | 61.83M | 45.82M | 7.27M | 8.19M | 20.30M |
| Short-Term Investments | 81.54M | 78.57M | 14.40M | 4.93M | ||
| Cash & Short-Term Investments | 134.30M | 140.40M | 60.21M | 7.27M | 13.12M | 20.30M |
| Other Current Assets | 464.73K | 63.74K | 78.87K | 66.43K | 45.98K | 217.75K |
| Total Current Assets | 134.76M | 140.46M | 60.29M | 7.33M | 13.17M | 20.52M |
| Property, Plant & Equipment | 215.12K | 254.92K | 12.65K | 61.23K | ||
| Total Assets | 134.98M | 140.72M | 60.29M | 7.35M | 13.23M | 20.52M |
| Accounts Payable | 3.92M | 2.64M | 2.25M | 1.76M | 3.13M | 1.58M |
| Accrued Expenses | 3.00M | |||||
| Current Portion of Leases | 97.83K | 90.57K | ||||
| Total Current Liabilities | 4.02M | 2.74M | 5.25M | 1.76M | 3.13M | 1.58M |
| Long-Term Leases | 107.83K | 154.92K | 8.41K | |||
| Total Liabilities | 4.12M | 2.89M | 5.25M | 1.76M | 3.14M | 1.58M |
| Common Stock | 6.71K | 6.69K | 6.10K | 2.98K | 12.95K | 12.60K |
| Additional Paid-In Capital | 229.47M | 227.20M | 130.79M | 65.81M | 61.87M | 60.22M |
| Retained Earnings | -98.72M | -89.51M | -75.79M | -60.21M | -51.80M | -41.29M |
| Comprehensive Income & Other | 91.32K | 131.39K | 35.99K | -14.13K | 8.94K | -3.16K |
| Total Common Equity | 130.85M | 137.83M | 55.04M | 5.59M | 10.09M | 18.94M |
| Shareholders' Equity | 130.85M | 137.83M | 55.04M | 5.59M | 10.09M | 18.94M |
| Total Liabilities & Equity | 134.98M | 140.72M | 60.29M | 7.35M | 13.23M | 20.52M |
| Total Debt | 205.66K | 245.49K | 8.41K | |||
| Net Cash (Debt) | 134.09M | 140.15M | 60.21M | 7.27M | 13.11M | 20.30M |
| Net Cash Per Share | 16.38 | 18.91 | 15.89 | 2.63 | 5.15 | 8.14 |
| Filing Date Shares Outstanding | 6.71M | 6.69M | 6.11M | 3.49M | 2.64M | 2.52M |
| Total Common Shares Outstanding | 6.71M | 6.69M | 6.10M | 2.98M | 2.59M | 2.52M |
| Working Capital | 130.75M | 137.73M | 55.04M | 5.58M | 10.04M | 18.94M |
| Book Value Per Share | 19.50 | 20.60 | 9.02 | 1.87 | 3.90 | 7.52 |
| Tangible Book Value | 130.85M | 137.83M | 55.04M | 5.59M | 10.09M | 18.94M |
| Tangible Book Value Per Share | 19.50 | 20.60 | 9.02 | 1.87 | 3.90 | 7.52 |
Cash flow statement
Fiscal year January - December; amounts in USD.
| TTM | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 | |
|---|---|---|---|---|---|---|
| Net Income | -17.84M | -13.72M | -15.59M | -8.40M | -10.52M | -9.10M |
| Loss (Gain) From Sale of Investments | -2.01M | -716.46K | -9.02K | |||
| Stock-Based Compensation | 5.32M | 4.84M | 1.14M | 1.90M | 1.64M | 1.47M |
| Other Operating Activities | 1.00 | 4.55M | ||||
| Change in Accounts Payable | 2.37M | 388.22K | 506.79K | -1.33M | 1.48M | 403.97K |
| Change in Other Net Operating Assets | -17.75K | -2.99M | 2.99M | -20.41K | 167.52K | -86.20K |
| Operating Cash Flow | -12.18M | -12.20M | -6.40M | -7.86M | -7.23M | -7.32M |
| Investment in Securities | -65.78M | -63.45M | -14.34M | 4.93M | -4.92M | |
| Investing Cash Flow | -65.78M | -63.45M | -14.34M | 4.93M | -4.92M | |
| Issuance of Common Stock | 127.69M | 127.71M | 59.40M | 2.07M | 109.51K | 11.28M |
| Repurchase of Common Stock | -36.53M | -36.13M | -104.22K | -46.97K | -76.63K | -63.25K |
| Other Financing Activities | -338.15K | |||||
| Financing Cash Flow | 91.16M | 91.57M | 59.29M | 2.03M | 32.87K | 10.88M |
| Foreign Exchange Rate Adjustments | 61.10K | 97.27K | 494.00 | -16.80K | -3.48K | 4.62K |
| Net Cash Flow | 13.26M | 16.02M | 38.55M | -920.11K | -12.12M | 3.57M |
| Levered Free Cash Flow | -6.10M | -8.20M | -5.48M | -5.01M | -3.22M | -3.99M |
| Unlevered Free Cash Flow | -6.10M | -8.20M | -5.48M | -5.01M | -3.22M | -3.99M |
| Change in Working Capital | 2.35M | -2.61M | 3.50M | -1.35M | 1.65M | 317.77K |
Ratios
Fiscal year January - December; amounts in USD.
| TTM | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 | |
|---|---|---|---|---|---|---|
| Market Capitalization | 444.48M | 436.37M | 134.17M | 5.06M | 30.62M | 40.42M |
| Enterprise Value | 310.39M | 292.80M | 128.15M | -3.44M | 16.33M | 18.07M |
| Last Close Price | 70.32 | 65.30 | 22.00 | 1.70 | 11.85 | 16.05 |
| PB Ratio | 3.61 | 3.17 | 2.44 | 0.91 | 3.04 | 2.13 |
| P/TBV Ratio | 3.42 | 3.17 | 2.44 | 0.91 | 3.04 | 2.13 |
| Debt / Equity Ratio | 0.00 | 0.00 | 0.00 | |||
| Net Debt / Equity Ratio | -1.02 | -1.02 | -1.09 | -1.30 | -1.30 | -1.07 |
| Quick Ratio | 33.44 | 51.33 | 11.46 | 4.13 | 4.19 | 12.85 |
| Current Ratio | 33.56 | 51.35 | 11.47 | 4.17 | 4.21 | 12.98 |
| Return on Equity (ROE) | -19.50% | -14.22% | -51.42% | -107.19% | -72.45% | -52.57% |
| Return on Assets (ROA) | -14.64% | -10.39% | -29.87% | -53.66% | -39.03% | -30.51% |
| Return on Capital Employed (ROCE) | -16.90% | -12.10% | -29.40% | -158.00% | -104.30% | -48.20% |
| Earnings Yield | -3.29% | -3.14% | -11.62% | -166.13% | -34.34% | -22.52% |
| Buyback Yield / Dilution | -45.84% | -95.53% | -37.09% | -8.70% | -1.97% | -13.82% |